Navigation Links
Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies

OXFORD, England, May 18 /PRNewswire/ --

- New Alliance a Key Step for OBT to Broaden its Exciting Pipeline of Therapeutic Antibodies

Oxford BioTherapeutics (OBT) today announced a strategic alliance with GlaxoSmithKline to discover, develop and commercialise novel, therapeutic antibodies for the treatment of primary, metastatic and recurring forms of cancer.

Under the alliance, GSK will develop novel antibody therapies against selected OBT targets. In parallel OBT will develop one of its own monoclonal antibodies through to clinical proof of concept, at which point GSK will have an exclusive option to in-license this monoclonal antibody and will thereafter assume responsibility for further clinical development and commercialisation on a worldwide basis.

OBT will receive an undisclosed upfront payment and will be eligible for up to a total of $370m (GBP244m) upon the achievement of specified discovery, development, regulatory and commercialisation milestones.

In addition to the upfront and milestone payments, OBT will receive double-digit royalties on sales of any product that it develops to clinical proof of concept and single-digit royalties on worldwide sales of marketed GSK antibody products aimed at OBT targets. Furthermore, OBT may opt to carry forward the OBT or GSK collaboration programs that GSK chooses not to develop further.

The alliance integrates OBT's expertise in the discovery of novel oncology targets and therapeutic antibody discovery with GSK's in-house therapeutic antibody discovery and development capabilities. OBT's antibody discovery platform builds on its OGAP(R) proteomic database, which represents one of the world's largest proprietary human protein collections including data on 5,000 cancer membrane proteins combined with highly disease relevant genomic and clinical information derived from human blood and cancer tissue studies.

"We are extremely pleased to be collaborating with GSK given their proven commitment to innovation and their expertise in the development and commercialisation of novel oncology medicines," said Christian Rohlff, CEO of OBT.

"This strategic alliance provides important validation of our scientific expertise in the fields of cancer target discovery and broadens OBT's antibody pipeline. In addition, we gain access to significant non-dilutive financing to support the development of our pipeline of fully human therapeutic antibodies which we believe have the potential to significantly impact clinically unmet needs in certain important cancer indications."

About Oxford BioTherapeutics

Oxford BioTherapeutics (OBT) is focused on the development of targeted medicines for oncology. OBT's strategy is to develop innovative antibody-based cancer drugs, with integrated diagnostics, against novel targets that it has discovered in its unique OGAP(R) proteomic database. OBT, through its alliances with the world leaders in antibody development (Medarex, Biosite, Amgen and GSK), is in a strong position to convert its novel targets into a successful therapeutic pipeline. OBT's pipeline will deliver innovative and cost-effective medicines to fulfil major unmet patient needs in the field of cancer. OBT, a privately held company, was formed in 2004 and is based near Oxford, UK.

About OGAP(R)

The Oxford Genome Anatomy Project (OGAP(R)) database represents the world's largest proprietary collection of disease-associated proteins. It integrates genomic, proteomic and clinical information derived from blood and tissue studies for a large number of diseases from 50 different human tissues representing 60 diseases and contains over one million peptide sequences, mapped to approximately 15,000 genes, combined with over eight million SNPs and haplotypes. OGAP(R) oncology contains proteomic data on 5,000 cancer membrane proteins combined with their genomic and clinical information derived from human blood and cancer tissue studies.

OGAP(R) is a registered trade mark of Oxford BioTherapeutics Ltd.

For further information, please see or

    Oxford BioTherapeutics Enquiries:

    Chief Executive Officer:    Christian Rohlff, Ph.D.     +44(0)1235-861770

    Media enquiries/Citigate:   David Dible                +44(0)207-638-9571

SOURCE Oxford BioTherapeutics (OBT)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
2. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
3. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
6. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
7. Biotica Strikes Significant Collaboration Deal With GlaxoSmithKline
8. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
9. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
10. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
11. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
Post Your Comments:
(Date:12/1/2015)... --> --> ... by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, (Therapeutic ... Analysis - Global Forecast to 2020", published by MarketsandMarkets, the ... Million by 2020 from USD 40,281.6 Million in 2015, at ... Browse 37 market data T ...
(Date:12/1/2015)... , Dec. 1, 2015 Assurex ... its GeneSight® Psychotropic test giving healthcare providers an expanded ... decisions for patients suffering from depression, anxiety, bipolar ... behavioral health conditions. i . ... --> With the addition of two new ...
(Date:12/1/2015)... , Dec. 1, 2015  Six months of adjunctive ... with type 1 diabetes, according to new research from ... However, it may have a beneficial effect on measures of ... current issue of the Journal of the American Medical ... examining the effect of metformin on overweight and obese adolescents ...
Breaking Medicine Technology:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Dr. Paul ... Vitenas Cosmetic Surgery, has been named by MedEsthetics magazine as the Best Single Physician ... the best among the many elite aesthetic physicians honored by the industry publication. ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 ... of the company’s growing product line of food safety and seafood fraud prevention ... (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for the ...
(Date:12/1/2015)... ... ... It’s official: Tattoo taboo is a thing of the past. One in ... whopping one in three aged 18 to 25 is inked). As tattoos transition to ... In fact, RealSelf , the world’s largest community for learning and sharing information ...
(Date:12/1/2015)... ... , ... The importance of volumetric breast density assessment for ... abstracts accepted for presentation here, at the 101st Annual Radiology Society of North ... of Volpara Solutions’ quantitative breast imaging software tools for providing breast imaging and ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... scale , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus ... imaging results enhancements at the Radiological Society of North America (RSNA) 2015 annual ...
Breaking Medicine News(10 mins):